Veraxa (VRXA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

$180,498.00

Net income growth (year over year)

−92.58%

Net margin

—

Return on equity

—

EPS (trailing twelve months)

−$5.88

Book value per share

−$0.46

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

105.31%

Payout ratio

—

Dividend yield

—

Company profile

Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.

• How do I buy stock in Veraxa (VRXA)?

  VRXA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.